You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復旦張江(01349.HK)簽署柏金遜症新藥合作項目
復旦張江(01349.HK)公布,擬與其持股39.5663%的參股公司「上海漢都」進行項目合作並簽署相關協議,合作標的為上海漢都在研的一項用於治療柏金遜症的新藥(擬命名為「卡左雙多巴控釋片」)。 公司將在上海漢都完成II期臨床試驗並取得預期效果的基礎上,開展III期臨床實驗,若最終順利完成該項目,公司將成為許可產品在中國內地的藥品上市許可持有人並負責許可產品的相關生產銷售。 自許可產品在許可區域內首次上市銷售後累計淨利潤為正數的第一個日曆年末開始,復旦張江應向上海漢都支付其在許可區域的每個日曆年內銷售許可產品的淨利潤的50%,若發生虧損,則上市公司無需向上海漢都支付上述款項。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account